BioSpace News Archive

Medicure today announced that it has received the deferred purchase price proceeds of approximately US$50 million from the sale of its interests in Apicore to an arm’s length, pharmaceutical company (the “Buyer”), a transaction that closed and was announced in October 2017.

Mr. Barhorst brings in depth finance and governance experience gained during a career in the financial markets.

Results showed evidence of antitumor activity in both animals in the preclinical study.

This secondary endpoint analysis demonstrated that the addition of Optune to temozolomide did not negatively impact health-related quality of life, except for itchy skin under Optune’s transducer arrays.

Siemens Healthineers announced today it has received 510(k) clearance from the U.S. Food and Drug Administration for its Blood Urea Nitrogen (BUN) and Total Carbon Dioxide (TCO2) point-of-care tests to aid in the diagnosis of renal diseases and metabolic imbalances.

In the study, animals treated with the Company’s non-invasive medical device one or two times per day for 28 days had significantly smaller (by 36.4%, p<0.01) infarcts versus the controls.

A live webcast can be accessed under “Events & Presentations” in the Investors section of the company’s website.

The milestone payment of US$1 million relates to the clinical development of eftilagimod alpha in China and follows the granting of EOC Pharma’s Investigational New Drug (IND) application in China, as outlined in Immutep’s December 12, 2017 Operational Update.

Global leaders, patient safety experts, hospital and medical technology CEOs and patient advocates will gather to address the challenges that cause medical errors and preventable deaths in hospitals worldwide at the 6th Annual World Patient Safety, Science & Technology Summit in London on February 23-25, 2018.

The abstract showcases the potential of Actinium’s AWE Technology Platform, specifically, the ability of actinium-225 to enhance the in vivo efficacy of daratumumab, a CD38 targeting therapy that is marketed by Johnson & Johnson as Darzalex®.